Ultragenyx Pharmaceutical
Earnings Surprise
Analysts estimated RARE earnings of $-1.54 per share this quarter (Q1). RARE's actual earnings were $-1.84 per share.
RARE EPS surprise of -19.49%Analysts estimated RARE earnings of $-1.11 per share this quarter (Q4). RARE's actual earnings were $-1.29 per share.
RARE EPS surprise of -15.82%Analysts estimated RARE earnings of $-1.26 per share this quarter (Q3). RARE's actual earnings were $-1.81 per share.
RARE EPS surprise of -43.74%Analysts estimated RARE earnings of $-1.32 per share this quarter (Q2). RARE's actual earnings were $-1.17 per share.
RARE EPS surprise of 11.68%Analysts estimated RARE earnings of $-1.32 per share this quarter (Q4). RARE's actual earnings were $-1.39 per share.
RARE EPS surprise of -5.62%Analysts estimated RARE earnings of $-1.48 per share this quarter (Q3). RARE's actual earnings were $-1.40 per share.
RARE EPS surprise of 5.37%Analysts estimated RARE earnings of $-1.73 per share this quarter (Q2). RARE's actual earnings were $-1.52 per share.
RARE EPS surprise of 12.01%Analysts estimated RARE earnings of $-1.77 per share this quarter (Q1). RARE's actual earnings were $-2.03 per share.
RARE EPS surprise of -14.94%Analysts estimated RARE earnings of $-1.65 per share this quarter (Q4). RARE's actual earnings were $-1.52 per share.
RARE EPS surprise of -7.99%